Clinical Trial Update: An Open-label, Dose-Escalation and Dose-Expansion Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

An open-label Phase 1/2 dose-escalation and dose-expansion study of GB3226 in relapsed/refractory acute myeloid leukemia; trial status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• GB3226 (GB3226)

Snippet

Sponsor: Galecto Biotech AB | Conditions: Relapsed/Refractory Acute Myeloid Leukemia (AML) | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING